<DOC>
	<DOCNO>NCT01719757</DOCNO>
	<brief_summary>The aim study evaluate efficacy TARGIN administration analgesic Korean patient treat opioid analgesic moderate-to-severe cancer pain condition daily practice .</brief_summary>
	<brief_title>PROspective Non-interventional Open laBEl Trial TARGIN Korean Patients With Cancer Pain</brief_title>
	<detailed_description>An open-label , multi-center , nonrandomized , prospective , non-interventional , observational phase IV trial . At first visit , detailed medical history take , include previous analgesic concomitant treatment . After inclusion , patient enter 4-week observation period receive bid TARGIN 10/5mg and/or 20/10mg . The dose adjustment TARGIN well analgesic co-medication , rescue-medication treatment ( e.g . laxative ) perform time-point observation period physician dependence medical demand . The asymmetric dose allow observation period physician 's judgment . ( e.g . 10/5 mg morning 20/10 mg evening ) . Data gather use interview-administered questionnaire baseline ( visit 1 ) study end ( visit 2 ) . During observation period , unscheduled visit allow first visit due inadequate pain control occurrence adverse event .</detailed_description>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>1 . Male female cancer patient 20 year age old 2 . Cancer relate pain require treatment continuous aroundtheclock strong opioid analgesic 3 . Moderate severe pain intensity ( NRS pain score &gt; =4 ) 4 . Opioid na√Øve patient patient treat strong opioids ( Only except occasional PRN ) within 13 month patient weak opioids 5 . Ability communicate effectively study personnel regard pain intensity , constipation assessment , final assessment overall efficacy tolerability 6 . Subject provide sign dated write voluntary inform consent 1 . Pregnant nursing ( lactate ) woman 2 . Have previously receive treatment Targin 3 . Patient evidence significant structural/functional abnormality GI tract appropriate oral medicine administration 4 . Any history hypersensitivity Oxycodone Naloxone excipients 5 . Patients significant respiratory depression 6 . Patients acute severe bronchial asthma hypercarbia 7 . Any patient suspect paralytic ileus 8 . Severe Chronic obstructive pulmonary disease , pulmonary heart disease 9 . Targin product contains lactose . Patients rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption take 10 . Patients moderate severe hepatic impairment 11 . Abnormal aspartate aminotransferase ( AST ; SGOT ) , alanine aminotransferase ( ALT ; SGPT ) , alkaline phosphatase level ( &gt; 2.5 time upper limit normal , allow &gt; 5 time upper limit normal case transition liver ) abnormal total bilirubin and/or creatinine level ( ) ( great 1.5 time upper limit normal ) 12 . Any situation opioids contraindicate 13 . With life expectancy &lt; 1 month 14 . Any situation opioids contraindicate 15 . Mainly pain originated cancer cancer relate condition ( eg . Musculoskeletal pain , inflammatory pain , diabetic polyneuropathy ) 16 . Patients know suspected unstable brain metastasis spinal cord compression may require change steroid treatment throughout duration study 17 . Patients uncontrolled seizure 18 . Requiring interventional treatment pain neurodestructive procedure regional infusion 19 . With history alcohol abuse within 6 month screen 20 . With history illicit drug abuse within 6 month screen 21 . Patients increase intracranial pressure 22 . Having use investigational drug time enrollment , within 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Targin , Cancer Pain</keyword>
</DOC>